menu
    • menu
    [{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"SymBio Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"SymBio Pharmaceuticals \/ SymBio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SymBio Pharmaceuticals \/ SymBio Pharmaceuticals"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SyB V-1901","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by SymBio Pharmaceuticals

    Menu

    SymBio Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed ...

                            Details : Brincidofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia)...

                            Details : Brincidofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of BK Virus Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2022

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

                            Details : Brincidofovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Adenoviridae Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2021

                            Lead Product(s) : Brincidofovir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bendamustine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Eagle Pharmaceuticals

                            Deal Size : $17.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eagle Pharmaceuticals’ Licensing Partner, SymBio, Gets Approval of TREAKISYM Ready-To-Dilute Formulation

                            Details : With this approval, SymBio will convert its current lyophilized formulation of TREAKISYM to the new RTD liquid formulation upon launch in January 2021.

                            Product Name : Bendeka

                            Product Type : Miscellaneous

                            Upfront Cash : $12.5 million

                            September 23, 2020

                            Lead Product(s) : Bendamustine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Eagle Pharmaceuticals

                            Deal Size : $17.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SyB V-1901

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy S...

                            Details : SyB V-1901 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 09, 2020

                            Lead Product(s) : SyB V-1901

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed

                            SymBio Pharmaceuticals

                            Japan arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bendamustine Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment f...

                            Details : SymBio Pharmaceuticals Limited has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion in Japan. Company plans to submit a New Drug Application for the product.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 30, 2020

                            Lead Product(s) : Bendamustine Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth